{"id":20454,"date":"2025-09-03T12:30:16","date_gmt":"2025-09-03T12:30:16","guid":{"rendered":"https:\/\/itbusinesstoday.com\/?p=20454"},"modified":"2025-09-03T12:30:42","modified_gmt":"2025-09-03T12:30:42","slug":"eisai-seeks-fda-approval-for-leqembi-subcutaneous-dose","status":"publish","type":"post","link":"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/eisai-seeks-fda-approval-for-leqembi-subcutaneous-dose\/","title":{"rendered":"LEQEMBI\u76ae\u4e0b\u6295\u4e0e\u306b\u95a2\u3059\u308bFDA\u306e\u627f\u8a8d\u7533\u8acb\u306b\u3064\u3044\u3066"},"content":{"rendered":"<p>\u30a8\u30fc\u30b6\u30a4\u682a\u5f0f\u4f1a\u793e\uff08\u672c\u793e\uff1a\u6771\u4eac\u90fd\u3001\u793e\u9577\uff1a\u5185\u85e4\u6674\u592b\uff09\u3068\u30d0\u30a4\u30aa\u30b8\u30a7\u30f3\u30fb\u30a4\u30f3\u30af\uff08\u672c\u793e\uff1a\u7c73\u56fd\u30de\u30b5\u30c1\u30e5\u30fc\u30bb\u30c3\u30c4\u5dde\u3001\u4f1a\u9577\u517cCEO\uff1a\u30ea\u30c1\u30e3\u30fc\u30c9\u30fb\u30a6\u30a9\u30fc\u30ea\u30fc\uff09\u306f\u3001\u3053\u306e\u305f\u3073\u3001\u7c73\u56fdFDA\u306b\u751f\u7269\u5b66\u7684\u88fd\u5264\u8ffd\u52a0\u627f\u8a8d\u7533\u8acb\uff08sBLA\uff09\u3092\u958b\u59cb\u3057\u307e\u3057\u305f\u3002\u672c\u7533\u8acb\u306f\u3001LEQEMBI\u00ae IQLIK\u2122\uff08\u4e00\u822c\u540d\uff1alecanemab-irmb\uff09\u306e\u65e9\u671f\u30a2\u30eb\u30c4\u30cf\u30a4\u30de\u30fc\u578b\u8a8d\u77e5\u75c7\u60a3\u8005\u69d8\u306b\u5bfe\u3059\u308b\u76ae\u4e0b\u6295\u4e0e\u958b\u59cb\u7528\u91cf\u306b\u95a2\u3059\u308b\u3082\u306e\u3067\u3059\u3002FDA\u306f\u672c\u7533\u8acb\u306b\u30d5\u30a1\u30b9\u30c8\u30fb\u30c8\u30e9\u30c3\u30af\u306e\u30b9\u30c6\u30fc\u30bf\u30b9\u3092\u4ed8\u4e0e\u3057\u307e\u3057\u305f\u3002LEQEMBI\u306f\u8efd\u5ea6\u8a8d\u77e5\u969c\u5bb3\u307e\u305f\u306f\u8efd\u5ea6\u8a8d\u77e5\u75c7\u306e\u60a3\u8005\u3055\u3093\u306e\u30a2\u30eb\u30c4\u30cf\u30a4\u30de\u30fc\u75c5\u6cbb\u7642\u85ac\u3067\u3059\u3002\u3053\u308c\u306f\u65e9\u671fAD\u3068\u547c\u3070\u308c\u307e\u3059\u3002<\/p>\n<p>\u672c\u7533\u8acb\u306b\u306f\u3001\u7570\u306a\u308b\u7528\u91cf\u306elecanemab\u76ae\u4e0b\u6295\u4e0e\u306b\u95a2\u3059\u308b\u81e8\u5e8a\u30c7\u30fc\u30bf\u304c\u542b\u307e\u308c\u3066\u3044\u307e\u3059\u3002\u3053\u306e\u30c7\u30fc\u30bf\u306f\u3001\u7b2c3\u76f8Clarity AD\u8a66\u9a13\u306b\u304a\u3051\u308b18\u30ab\u6708\u9593\u306e\u30b3\u30a2\u8a66\u9a13\u5f8c\u306e\u975e\u76f2\u691c\u5ef6\u9577\u8a66\u9a13\u306b\u304a\u3051\u308b\u30b5\u30d6\u8a66\u9a13\u304b\u3089\u5f97\u3089\u308c\u305f\u3082\u306e\u3067\u3059\u3002\u627f\u8a8d\u3055\u308c\u308c\u3070\u3001LEQEMBI IQLIK 500mg\u30ec\u30b8\u30e1\u30f3\u306f\u65b0\u305f\u306a\u9078\u629e\u80a2\u3068\u306a\u308a\u307e\u3059\u3002\u3053\u306e\u30ec\u30b8\u30e1\u30f3\u306f\u3001250mg\u81ea\u52d5\u6ce8\u5c04\u5668\u30922\u672c\u4f7f\u7528\u3057\u3001\u90311\u56de\u6295\u4e0e\u3057\u307e\u3059\u3002\u3053\u308c\u306f\u3001\u73fe\u5728\u306e2\u9031\u9593\u306b1\u56de\u306e\u9759\u8108\u5185\u6295\u4e0e\u306b\u4ee3\u308f\u308b\u3082\u306e\u3067\u3059\u3002\u60a3\u8005\u3084\u4ecb\u8b77\u8005\u306f\u3001\u81ea\u5b85\u3067\u306e\u70b9\u6ef4\u304b\u76ae\u4e0b\u6295\u4e0e\u306e\u3044\u305a\u308c\u304b\u3092\u9078\u629e\u3067\u304d\u307e\u3059\u3002\u5404\u81ea\u52d5\u6ce8\u5c04\u5668\u306f\u7d0415\u79d2\u3067\u6295\u4e0e\u91cf\u3092\u6295\u4e0e\u3057\u307e\u3059\u3002\u3053\u308c\u306b\u3088\u308a\u3001\u8f38\u6db2\u95a2\u9023\u306e\u533b\u7642\u8cc7\u6e90\u306e\u5fc5\u8981\u6027\u304c\u6e1b\u308a\u3001\u6cbb\u7642\u304c\u5bb9\u6613\u306b\u306a\u308b\u53ef\u80fd\u6027\u304c\u3042\u308a\u307e\u3059\u3002<\/p>\n<p>\u30a2\u30eb\u30c4\u30cf\u30a4\u30de\u30fc\u75c5\u306f\u9032\u884c\u6027\u306e\u8133\u75be\u60a3\u3067\u3059\u3002\u30a2\u30df\u30ed\u30a4\u30c9\u03b2\u3068\u30bf\u30a6\u306e\u84c4\u7a4d\u304c\u7279\u5fb4\u3067\u3059\u3002\u3053\u306e\u84c4\u7a4d\u306f\u7d99\u7d9a\u7684\u306a\u795e\u7d4c\u6bd2\u6027\u306b\u3064\u306a\u304c\u308a\u307e\u3059\u3002LEQEMBI\u306f\u30a2\u30df\u30ed\u30a4\u30c9\u30fb\u30d7\u30e9\u30fc\u30af\u3068\u30d7\u30ed\u30c8\u30d5\u30a3\u30d6\u30ea\u30eb\u306e\u4e21\u65b9\u3092\u6a19\u7684\u3068\u3057\u307e\u3059\u3002\u30d7\u30ed\u30c8\u30d5\u30a3\u30d6\u30ea\u30eb\u306f\u30a2\u30df\u30ed\u30a4\u30c9\u03b2\u306e\u6700\u3082\u6709\u5bb3\u306a\u5f62\u614b\u3067\u3059\u3002\u30d7\u30ed\u30c8\u30d5\u30a3\u30d6\u30ea\u30eb\u306f\u8a8d\u77e5\u6a5f\u80fd\u306e\u4f4e\u4e0b\u306b\u91cd\u8981\u306a\u5f79\u5272\u3092\u679c\u305f\u3057\u307e\u3059\u3002LEQEMBI\u306f\u30d7\u30ed\u30c8\u30d5\u30a3\u30d6\u30ea\u30eb\u3092\u6a19\u7684\u3068\u3057\u3066\u3001\u795e\u7d4c\u7d30\u80de\u969c\u5bb3\u3092\u8efd\u6e1b\u3057\u3001\u75be\u60a3\u306e\u9032\u884c\u3092\u9045\u3089\u305b\u307e\u3059\u3002<\/p>\n<h4>\u3053\u3061\u3089\u3082\u304a\u8aad\u307f\u304f\u3060\u3055\u3044\uff1a <a class=\"p-url\" href=\"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/medipal-and-jcr-ink-global-deal-for-gm2-drug-jr-479\/\" rel=\"bookmark\">\u30e1\u30c7\u30a3\u30d1\u30eb\u3068JCR\u3001GM2\u6cbb\u7642\u85acJR-479\u306e\u30b0\u30ed\u30fc\u30d0\u30eb\u5951\u7d04\u3092\u7de0\u7d50<\/a><\/h4>\n<p>LEQEMBI\u306f48\u30ab\u56fd\u3067\u627f\u8a8d\u3055\u308c\u3066\u3044\u307e\u3059\u3002\u3055\u3089\u306b10\u30ab\u56fd\u3067\u5be9\u67fb\u4e2d\u3002 <a href=\"https:\/\/www.eisai.com\/\">\u30a8\u30fc\u30b6\u30a4\u00a0<\/a> \u306f\u3001lecanemab \u306e\u30b0\u30ed\u30fc\u30d0\u30eb\u306a\u958b\u767a\u304a\u3088\u3073\u898f\u5236\u306b\u95a2\u3059\u308b\u696d\u52d9\u3092\u7ba1\u7406\u3057\u3066\u3044\u307e\u3059\u3002\u540c\u793e\u306f\u307e\u305f\u3001\u672c\u6cbb\u7642\u85ac\u306e\u5171\u540c\u5546\u696d\u5316\u304a\u3088\u3073\u5171\u540c\u8ca9\u4fc3\u3092\u4ee5\u4e0b\u306e\u4f01\u696d\u3068\u884c\u3063\u3066\u3044\u307e\u3059\u3002 <a href=\"https:\/\/www.biogen.com\/\">\u30d0\u30a4\u30aa\u30b8\u30a7\u30f3<\/a>.\u3053\u306e\u30d1\u30fc\u30c8\u30ca\u30fc\u30b7\u30c3\u30d7\u306e\u6700\u7d42\u6c7a\u5b9a\u6a29\u306f\u30a8\u30fc\u30b6\u30a4\u306b\u3042\u308a\u307e\u3059\u3002<\/p>\n<p>&nbsp;<\/p>","protected":false},"excerpt":{"rendered":"<p>Eisai Co., Ltd. and Biogen Inc. have started a rolling supplemental Biologics License Application (sBLA) with the U.S. FDA. This is for LEQEMBI\u00ae IQLIK\u2122 (lecanemab-irmb) as a starting subcutaneous dose for patients with early Alzheimer\u2019s disease. The FDA gave Fast Track status to this application. LEQEMBI is for treating Alzheimer\u2019s disease in patients with mild cognitive impairment or mild dementia. This is called early AD. The submission has clinical data on subcutaneous lecanemab at different doses. This data comes from sub-studies in the Phase 3 Clarity AD open-label extension after the 18-month core trial. If approved, the LEQEMBI IQLIK 500 mg regimen would offer a new option. It uses two [&hellip;]<\/p>\n","protected":false},"author":7,"featured_media":20455,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_topic_count_hidden":0,"_bbp_reply_count_hidden":0,"_bbp_forum_subforum_count":0,"wprm-recipe-roundup-name":"","wprm-recipe-roundup-description":"","postBodyCss":"","postBodyMargin":[],"postBodyPadding":[],"postBodyBackground":{"backgroundType":"classic","gradient":""},"footnotes":""},"categories":[89,207,237,182],"tags":[872,7394,1715,7393,424],"ppma_author":[572],"class_list":{"0":"post-20454","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-health-tech","8":"category-international","9":"category-news","10":"category-pharma","11":"tag-alzheimer-disease","12":"tag-biogen","13":"tag-eisai","14":"tag-leqembi","15":"tag-pharma"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Eisai Files FDA Request for LEQEMBI Subcutaneous Dose<\/title>\n<meta name=\"description\" content=\"Eisai begins FDA rolling submission for LEQEMBI IQLIK, a subcutaneous dose for early Alzheimer\u2019s, following Fast Track designation.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/eisai-seeks-fda-approval-for-leqembi-subcutaneous-dose\/\" \/>\n<meta property=\"og:locale\" content=\"ja_JP\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eisai Files FDA Request for LEQEMBI Subcutaneous Dose\" \/>\n<meta property=\"og:description\" content=\"Eisai begins FDA rolling submission for LEQEMBI IQLIK, a subcutaneous dose for early Alzheimer\u2019s, following Fast Track designation.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/eisai-seeks-fda-approval-for-leqembi-subcutaneous-dose\/\" \/>\n<meta property=\"og:site_name\" content=\"itbusinesstoday\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-03T12:30:16+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-03T12:30:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/09\/Eisai-Initiated-Rolling-Supplemental-Biologics-License-Application-to-the.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"ITBT StaffWriter\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u57f7\u7b46\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"ITBT StaffWriter\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593\" \/>\n\t<meta name=\"twitter:data2\" content=\"2\u5206\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"LEQEMBI\u76ae\u4e0b\u6295\u4e0e\u306b\u95a2\u3059\u308bFDA\u3078\u306e\u7533\u8acb\u306b\u3064\u3044\u3066","description":"\u65e9\u671f\u30a2\u30eb\u30c4\u30cf\u30a4\u30de\u30fc\u578b\u8a8d\u77e5\u75c7\u6cbb\u7642\u5264\u300cLEQEMBI IQLIK\u300d\u3001\u30d5\u30a1\u30b9\u30c8\u30c8\u30e9\u30c3\u30af\u6307\u5b9a\u5f8c\u3001FDA\u306b\u7533\u8acb\u958b\u59cb.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/eisai-seeks-fda-approval-for-leqembi-subcutaneous-dose\/","og_locale":"ja_JP","og_type":"article","og_title":"Eisai Files FDA Request for LEQEMBI Subcutaneous Dose","og_description":"Eisai begins FDA rolling submission for LEQEMBI IQLIK, a subcutaneous dose for early Alzheimer\u2019s, following Fast Track designation.","og_url":"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/eisai-seeks-fda-approval-for-leqembi-subcutaneous-dose\/","og_site_name":"itbusinesstoday","article_published_time":"2025-09-03T12:30:16+00:00","article_modified_time":"2025-09-03T12:30:42+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/09\/Eisai-Initiated-Rolling-Supplemental-Biologics-License-Application-to-the.webp","type":"image\/webp"}],"author":"ITBT StaffWriter","twitter_card":"summary_large_image","twitter_misc":{"\u57f7\u7b46\u8005":"ITBT StaffWriter","\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593":"2\u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/eisai-seeks-fda-approval-for-leqembi-subcutaneous-dose\/#article","isPartOf":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/eisai-seeks-fda-approval-for-leqembi-subcutaneous-dose\/"},"author":{"name":"ITBT StaffWriter","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/person\/94fb575e469aff25a4b938814d050f15"},"headline":"Eisai seeks FDA approval for LEQEMBI Subcutaneous dose","datePublished":"2025-09-03T12:30:16+00:00","dateModified":"2025-09-03T12:30:42+00:00","mainEntityOfPage":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/eisai-seeks-fda-approval-for-leqembi-subcutaneous-dose\/"},"wordCount":276,"publisher":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#organization"},"image":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/eisai-seeks-fda-approval-for-leqembi-subcutaneous-dose\/#primaryimage"},"thumbnailUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/09\/Eisai-Initiated-Rolling-Supplemental-Biologics-License-Application-to-the.webp","keywords":["Alzheimer disease","Biogen","Eisai","LEQEMBI","Pharma"],"articleSection":["Health Tech","International","News","Pharma"],"inLanguage":"ja"},{"@type":"WebPage","@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/eisai-seeks-fda-approval-for-leqembi-subcutaneous-dose\/","url":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/eisai-seeks-fda-approval-for-leqembi-subcutaneous-dose\/","name":"LEQEMBI\u76ae\u4e0b\u6295\u4e0e\u306b\u95a2\u3059\u308bFDA\u3078\u306e\u7533\u8acb\u306b\u3064\u3044\u3066","isPartOf":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#website"},"primaryImageOfPage":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/eisai-seeks-fda-approval-for-leqembi-subcutaneous-dose\/#primaryimage"},"image":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/eisai-seeks-fda-approval-for-leqembi-subcutaneous-dose\/#primaryimage"},"thumbnailUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/09\/Eisai-Initiated-Rolling-Supplemental-Biologics-License-Application-to-the.webp","datePublished":"2025-09-03T12:30:16+00:00","dateModified":"2025-09-03T12:30:42+00:00","description":"\u65e9\u671f\u30a2\u30eb\u30c4\u30cf\u30a4\u30de\u30fc\u578b\u8a8d\u77e5\u75c7\u6cbb\u7642\u5264\u300cLEQEMBI IQLIK\u300d\u3001\u30d5\u30a1\u30b9\u30c8\u30c8\u30e9\u30c3\u30af\u6307\u5b9a\u5f8c\u3001FDA\u306b\u7533\u8acb\u958b\u59cb.","breadcrumb":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/eisai-seeks-fda-approval-for-leqembi-subcutaneous-dose\/#breadcrumb"},"inLanguage":"ja","potentialAction":[{"@type":"ReadAction","target":["https:\/\/itbusinesstoday.com\/health-tech\/pharma\/eisai-seeks-fda-approval-for-leqembi-subcutaneous-dose\/"]}]},{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/eisai-seeks-fda-approval-for-leqembi-subcutaneous-dose\/#primaryimage","url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/09\/Eisai-Initiated-Rolling-Supplemental-Biologics-License-Application-to-the.webp","contentUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/09\/Eisai-Initiated-Rolling-Supplemental-Biologics-License-Application-to-the.webp","width":1200,"height":800,"caption":"Eisai"},{"@type":"BreadcrumbList","@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/eisai-seeks-fda-approval-for-leqembi-subcutaneous-dose\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/itbusinesstoday.com\/"},{"@type":"ListItem","position":2,"name":"Eisai seeks FDA approval for LEQEMBI Subcutaneous dose"}]},{"@type":"WebSite","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#website","url":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/","name":"\u30a4\u30c3\u30c8\u30d3\u30b8\u30cd\u30b9\u30c8\u30a5\u30c7\u30a4","description":"","publisher":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ja"},{"@type":"Organization","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#organization","name":"\u30a4\u30c3\u30c8\u30d3\u30b8\u30cd\u30b9\u30c8\u30a5\u30c7\u30a4","url":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/","logo":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/logo\/image\/","url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Asset-1.png","contentUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Asset-1.png","width":663,"height":275,"caption":"itbusinesstoday"},"image":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/person\/94fb575e469aff25a4b938814d050f15","name":"ITBT\u30b9\u30bf\u30c3\u30d5\u30e9\u30a4\u30bf\u30fc","image":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Favicon-1.png90b3cb23d1d9c08733d969d29ea2d30d","url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Favicon-1.png","contentUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Favicon-1.png","caption":"ITBT StaffWriter"},"description":"ITBT\u30b9\u30bf\u30c3\u30d5\u30e9\u30a4\u30bf\u30fc\u306f\u3001IT Business Today\u306e\u793e\u5185\u5bc4\u7a3f\u8005\u3067\u3001\u30bf\u30a4\u30e0\u30ea\u30fc\u306a\u30cb\u30e5\u30fc\u30b9\u3068QuickBytes\u306e\u914d\u4fe1\u3092\u62c5\u5f53\u3057\u3066\u3044\u307e\u3059\u3002IT\u3001\u30cf\u30a4\u30c6\u30af\u3001\u4f01\u696d\u30bd\u30ea\u30e5\u30fc\u30b7\u30e7\u30f3\u306e\u6700\u65b0\u52d5\u5411\u3092\u30ab\u30d0\u30fc\u3057\u3001\u7c21\u6f54\u3067\u30a4\u30f3\u30d1\u30af\u30c8\u306e\u3042\u308b\u6700\u65b0\u60c5\u5831\u3092\u8aad\u8005\u306b\u63d0\u4f9b\u3057\u3066\u3044\u307e\u3059\u3002","sameAs":["https:\/\/itbusinesstoday.com\/"],"url":"https:\/\/itbusinesstoday.com\/ja\/author\/itbt-staffwriter\/"}]}},"authors":[{"term_id":572,"user_id":7,"is_guest":0,"slug":"itbt-staffwriter","display_name":"ITBT StaffWriter","avatar_url":{"url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Favicon-1.png","url2x":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Favicon-1.png"},"0":null,"1":"","2":"","3":"","4":"","5":"","6":"","7":"","8":""}],"_links":{"self":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts\/20454","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/comments?post=20454"}],"version-history":[{"count":3,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts\/20454\/revisions"}],"predecessor-version":[{"id":20468,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts\/20454\/revisions\/20468"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/media\/20455"}],"wp:attachment":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/media?parent=20454"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/categories?post=20454"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/tags?post=20454"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/ppma_author?post=20454"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}